CD44/JAK2/STAT3 signaling pathway

Overview

The CD44/JAK2/STAT3 signaling pathway is a cell-signaling axis centered on the transmembrane adhesion receptor CD44 and the intracellular kinases/transcription factors JAK2 and signal transducer and activator of transcription 3 (STAT3). In biomedical research, this pathway is commonly discussed as a regulator of cell survival, proliferation, inflammatory signaling, stem-like phenotypes, immune-cell polarization, and tumor progression. CD44 is frequently implicated in hyaluronan-dependent cell interactions and tumor microenvironment signaling, while JAK2-mediated phosphorylation of signal transducer and activator of transcription 3 (STAT3) can drive transcriptional programs associated with inflammation and malignancy.

In recent literature, this pathway has been studied in cancer and inflammatory disease contexts, including thyroid cancer, pancreatic cancer, glioblastoma, acute myeloid leukemia, acute lymphoblastic leukemia, psoriasis, cutaneous T-cell lymphoma, and acute lung injury. It also appears in mechanistic studies of natural products and combination therapies that modulate IL-6/JAK2/signal transducer and activator of transcription 3 (STAT3), JAK2/signal transducer and activator of transcription 3 (STAT3), or CD44-linked signaling, often alongside related pathways such as PI3K/Akt signaling pathway, PI3K/AKT/mTOR pathway, TGFB1, interleukin-6, KRAS, and STAT5A.

Recent Publications Summary

Recent studies have examined the CD44/JAK2/STAT3 signaling pathway in diverse disease and therapeutic contexts, most often as part of broader signaling networks rather than as a sole intervention target. In cancer models, JAK2/STAT3 inhibition was linked to antiproliferative and pro-apoptotic effects in A549 lung cancer cells, where 3-deoxy-4-sulfonamido-butein derivatives induced G2/M arrest and apoptosis through suppression of the EGFR/JAK2/STAT3 axis 42044554Apr. In gastric cancer, ginkgetin was reported to induce immunogenic cell death while inhibiting STAT3 signaling 41946410Apr. In pancreatic ductal adenocarcinoma, a multi-target strategy combining KRAS, EGFR, and STAT3 inhibition produced complete regression and prevented resistance in orthotopic tumors, genetically engineered mouse tumors, and patient-derived xenografts, underscoring STAT3 as a key orthogonal node in KRAS-driven disease 42224594Jun. Additional work in pancreatic cancer also highlighted CD44-directed delivery approaches, including hyaluronic acid-modified nanoparticles carrying gemcitabine and paclitaxel 41966415Apr and hyaluronic acid-targeted CPD12C15 nanoparticles 42055152Apr, although these abstracts did not specifically report pathway modulation.

Outside oncology, the pathway was studied in inflammatory and immune-mediated settings. Xiao-bi decoction was reported to alleviate psoriasis by inhibiting JAK2/STAT3 signaling and rebalancing Th17/Treg responses 41785726Mar, while Danggui Buxue decoction was described as ameliorating blood deficiency syndrome through suppression of IL-6/JAK2/STAT3 signaling 41850643Mar. In sepsis-associated acute kidney injury, a biomimetic black phosphorus quantum dot nanozyme was designed to modulate the SIRT3/RORγt/STAT3 pathway to reduce Th17-driven inflammation 42093466May. In septic mice, moxibustion combined with anti-PD-1 antibody reduced PD-1, PD-L1, and STAT3 expression in the spleen and decreased STAT3 nuclear translocation, suggesting coordinated immune regulation through this axis 42307810Jun. A separate study in acute lung injury used hyaluronic acid-bilirubin nanoassemblies to exploit CD44-mediated uptake and modulate immune-epithelial interactions, but the abstract emphasized antioxidant and anti-inflammatory effects rather than direct JAK2/STAT3 targeting 41876009Mar.

Several publications also connected STAT3-centered signaling to macrophage biology, fibrosis, and neurologic injury. A fungal metabolite-based immunotherapy identified IM502 as a potent tumor-associated macrophage modulator that primarily inhibited PI3Kγ and shifted STAT signaling from STAT3/6 toward STAT1/2 dominance, reversing immunosuppression and enhancing NK and T-cell function 42173096May. In liver fibrosis, a ROS/pH-responsive hyaluronic acid-modified nanosystem was designed to target CD44-high activated hepatic stellate cells and remodel the microenvironment, with the abstract noting metabolic reprogramming and anti-inflammatory activity 41819037Mar. In ischemic stroke, high-frequency rTMS was reported to protect blood-brain barrier function via the miR-665/STAT3/MMP-9 axis 41974259Apr. In hematologic malignancy, ruxolitinib was used as a JAK1/JAK2 inhibitor in JAK2-mutant acute lymphoblastic leukemia, where it selectively reduced STAT5 phosphorylation and produced measurable biochemical changes detectable by Raman spectroscopy 41762803Feb. Finally, multiomic analysis of cutaneous T-cell lymphoma identified a gain-of-function STAT3 mutation and implicated PD-1 checkpoint pathways in progression and therapy resistance, reinforcing the relevance of STAT3-linked signaling in malignant immune evasion 41662591Feb.

What Changes, What Holds

1. STAT3 remains a central node, but the new work mostly extends its therapeutic reach rather than redefining the pathway
REINFORCES These studies keep the CD44/JAK2/STAT3 axis in the same conceptual space described in the Overview: a malignancy-linked signaling route that can be suppressed to limit proliferation, survival, and resistance. The added value is breadth and translational specificity, especially in lung, gastric, and pancreatic cancer, plus CD44-directed delivery strategies that fit the established role of CD44 in tumor targeting 42044554Apr42224594Jun.

2. Inflammatory disease studies strengthen the pathway’s role in immune polarization, while CD44-linked uptake remains a delivery feature rather than a new mechanism
REINFORCES The psoriasis and blood-deficiency findings align with the baseline view of JAK2/STAT3 as a regulator of inflammatory signaling and immune-cell balance. The acute lung injury nanoassembly and sepsis-related immune modulation add context, but they do not overturn the established account; they mainly show that CD44 can be exploited for targeting and that STAT3-centered control can be embedded in broader anti-inflammatory designs 41785726Mar41850643Mar.

3. STAT3-centered signaling is being used more broadly to explain immune suppression, fibrosis, and neurologic protection, but the baseline still stands
NEW DIRECTION These papers extend the pathway beyond the Overview’s named cancer and inflammatory settings into macrophage reprogramming, hepatic stellate-cell targeting, stroke, and checkpoint-associated immune evasion. That broadening does not contradict the established CD44/JAK2/STAT3 account; it shows that STAT3-linked biology is being applied to additional tissue contexts and cell states that the Overview did not explicitly cover 42173096May41974259Apr.